Membranoproliferative glomerulonephritis (MPGN) is characterized by mesangial cell proliferation and is classified into types I, II and III based on structural changes in the glomerular capillary walls. The drusen-like deposits of MPGN type II have been studied, but the fundus changes in MPGN type III have yet to be clarified. We report a case of MPGN type III with multiple deposits in the retinal pigment epithelium (RPE).
A 40-year-old Japanese woman with MPGN type III developed numerous yellow-white patches in the central macula of both eyes. Optical coherence tomography (OCT) showed deposits between the RPE and Bruch’s membrane. Fluorescein angiography showed choroidal neovascularization (CNV) and OCT confirmed it as type 1 (sub RPE) CNV with fibrin tissue and subretinal fluid in the right eye. After 12 months, the CNV and subretinal fluid resolved spontaneously but the RPE deposits remained in both eyes. Her final visual acuity was 20/20 in the right eye and 20/16 in the left eye.
We report a case of MPGN type III with multiple deposits in the RPE and CNV, suggesting that various fundus changes occur in MPGN type III and careful fundus follow-up is necessary to prevent vision loss.
Membranoproliferative glomerulonephritis (MPGN) is an uncommon kidney disorder characterized by mesangial cell proliferation with electron dense deposits and structural changes in the glomerular capillary walls. MPGN accounts for 4% of nephrosis in children and 7% nephrosis in adults, with higher prevalence in women . MPGN is clinically classified as either primary (idiopathic) or secondary MPGN , and histologically classified as types I, II and III according to the location of electron dense deposits . MPGN type II, also known as a dense deposit disease (DDD), is caused by abnormalities in the alternative complement pathway, resulting in deposition of complement C3 in the glomerular basement membrane. The etiologies of MPGN type III have not been fully elucidated, but are considered to be different from type II . Immune complex deposits were observed under glomerular endothelial cells in type I and under both glomerular endothelial cells and epithelial cells in type III. The disease demographics also vary between MPGN subtypes. Type I is found in adolescents and people in their 40s. Type II is commonly found in teenagers, many of which have highly active disease. Type III can occur at any age.
In previous studies, fundus abnormalities were mostly reported in MPGN type II, described as drusen-like deposits in the basement membrane of Bruch’s membrane and associated with choroidal neovascularization (CNV) and idiopathic central serous chorioretinopathy [5,6,7]. In MPGN type I, drusen-like deposits were also reported but the extent varied, ranging from no fundus abnormalities to extensive drusen-like deposits .
To our knowledge, there have been few reports describing fundus changes associated with MPGN type III . This case demonstrates MPGN type III with multiple retinal deposits and describes the 1 year follow-up findings.
A 40-year-old Japanese woman complained of bilateral metamorphopsia. She had bilateral retinochoroiditis with unknown origin and was referred to the Japanese Red Cross Medical Center, Department of Ophthalmology, Tokyo, Japan in December 2016. She had a history of proteinuria at age 8 and was diagnosed with MPGN type III by renal biopsy in 2011. The laboratory tests showed proteinuria (urinary protein 0.60 g/gCre) and hematuria. Urinalysis showed RBC count of 10-19/high power field (HPF) and WBC count of 1-4/HPF. Hemoglobin (13.4 g/dL), total protein (7.2 g/dL) and albumin (4.2 g/dL) were in normal ranges. Hepatitis B surface antigen and hepatitis C virus antibodies were negative. Immunoglobulin levels were in normal ranges (IgG 1290 mg/dL, IgA 367 mg/dL, IgM 129 mg/dL). Anti-nuclear antibody and anti-neutrophil cytoplasmic antibody were negative. Renal function was normal (blood urea nitrogen 20.0 mg/dL, serum creatinine 0.67 mg/dL, estimated glomerular filtration rate 80.1 mL/min). C3 levels (53 mg/dL) was low, and CH50 (44 U/m) and C4 (22.2 mg/dL) were normal. Renal biopsy showed a lobular appearance of the glomerular tuft with increased glomerular cellularity on hematoxylin and eosin (H&E) staining (Fig. 1a). Periodic acid methenamine silver (PAM) staining showed the double loop sign representing interposition of mesangial cell elements with new glomerular basement membrane synthesis (Fig. 1b and c, white arrow) and has a bubbling appearance (Fig. 1cblack arrow). Fluorescence immunostaining showed strong granular C3 staining in both mesangium and capillary loops (Fig. 1d). Electron microscopy showed proliferation of mesangial cells, mesangial expansion (Fig. 1e, star) and subepithelial immune deposits (Fig. 1f, black arrow). She received oral prednisolone 30 mg/day and was gradually tapered between January 2012 and February 2013. She had no family history or history of smoking.
In December 2016, her visual acuities were 20/20 OD and 20/16 OS. The intraocular pressures were 15 mmHg OD and 18 mmHg OS. Slit-lamp biomicroscopic exam revealed no abnormal findings in the anterior segment. No inflammatory cells were observed in the anterior chamber and vitreous cavity in both eyes. Fundus exam revealed numerous yellow-white granular patches at the central macula in both eyes (Fig. 2a and b). Fibrin tissue and a small hemorrhage was noted at the lower part of the central fovea of the right eye (Fig. 2a, white arrow). Fundus auto fluorescence (TRC-DX50, TOPCON, Fig. 2c and d) showed numerous granular hypofluorescence surrounded by a ring shaped hyperfluorescence in both eyes. Fluorescein angiography showed granular hyperfluorescence at the posterior pole of both eyes without fluorescein leakage in the late phase (Fig. 3a and b). Fluorescein leakage from CNV was noted at the inferior parafovea of the right eye (fig. 3a and c, white arrow). There was no leakage at the area of the ring shaped hyperfluorescences in the late phase of the left eye (Fig. 3d). Optical coherence tomography (OCT, CIRRUS HD-OCT model 4000, Carl Zeiss Meditec, Dublin, CA) showed various shaped protrusions of retinal pigment epithelium (RPE) in both eyes (Fig. 4a and b). Apical and basal borders of the RPE showed higher reflection than normal and granular hyperreflective substances were noted at the basal side of the RPE. There was low reflection between the basal side of RPE and Bruch’s membrane at the protruded lesion of RPE. Vertical scan imaging showed CNV and subretinal fluid in the right eye (Fig. 4c, arrow head) and fibrin tissue was noted above the CNV. Full field electroretinogram (ERG, TOMEY LE-2000, TOMEY, Nagaya, Japan) showed normal responses in both eyes.
Serous retinal detachment (SRD) in the right eye disappeared at 11 months after the initial visit and CNV in the right eye disappeared spontaneously with resolution of subretinal fluid at 12 months after the initial visit. (Fig. 5a and c). However, multiple dome-shaped elevations of RPE remained in both eyes (Fig. 5a-d). At 12 months after the initial visit, visual acuities were 20/16 OD and 20/16 OS and there was no recurrence of CNV with SRD.
MPGN, depending on the subtype, is progressive and has poor prognoses, and may share a common pathogenic mechanism. The presence of drusen-like deposits in MPGN type II is well-known. In 1989, Duvall-Young et al. reported drusen-like deposits in MPGN type II [9, 10] and demonstrated that these deposits shared a similar appearance to the deposits in the kidney on electron microscopy. However, there are few documented cases of MPGN type III with retinal changes. Michielsen et al. observed 17 patients with MPGN type III without fundus changes . However, Dalvin et al.  and our case report demonstrated drusenoid deposits in the RPE, suggesting that MPGN type III exhibits various fundus findings.
MPGN has traditionally been considered a group of morphologically classified diseases. Recently, the role of the complement system in MPGN has been recognized and there has been a proposed reclassification of MPGN as an immunoglobulin-mediated disease (via the classical complement pathway) and non-immunoglobulin-mediated disease (via the alternative complement pathway) [4, 12, 13]. Whereas MPGN type II results from disinhibition of the alternative complement pathway, MPGN types I and III results from circulating immune complex deposition that activates the classic complement pathway. MPGN type II is characterized by electron dense deposits of complement components in the glomerular basement membrane and Bruch’s membrane . Our case of MPGN type III showed fundus changes similar to those found in MPGN type II  rather than to MPGN type I . This variation of fundus changes ranging from no fundus abnormalities to multiple deposits supports the hypothesis of distinctive forms of glomerulonephritis with distinct etiologies, each varying in duration and disease severity .
Generally, the prognosis of visual acuity in MPGN type II is poor due to RPE detachment and CNV occurring in advanced stages [11, 15]. Based on the previous studies [4, 11], the prognosis of visual function in MPGN type III is thought to be better. However, our case of MPGN type III demonstrated CNV with SRD and multiple drusen-like deposits similar to fundus changes in MPGN type II. Those deposits resemble the drusen of age-related macular degeneration because their positions coincided with the drusen between the Bruch’s membrane and RPE in OCT (Fig. 4), although the content of the deposits were unknown. The deposits showed hypoflurescence at the center with surrounding hyperfluorescense in fundus autofluoresence imaging. This appearance was consistent with OCT findings that deposits showed higher reflectivity in the apical and basal sides and low reflectivity inside the deposits. A previous study reported that early laser treatment for an extrafoveal subretinal CNV and anti-VEGF intravitreal injection for subfoveal CNV was effective in treating MPGN type II [16, 17]. The CNV resolved spontaneously in this case similar to previous case report , but careful fundus follow-up and a laser treatment or anti-VEGF intravitreal injection may also may help prevent possible vision loss in MPGN type III.
In summary, we described a case of MPGN type III accompanied by multiple drusen-like deposits and protrusion of RPE associated with CNV and SRD. Retinal lesions due to MPGN may result in visual impairment, and it is very important to devise a logical treatment approach based on MPGN etiology.
Dense deposit disease
High power field
Optical coherent tomography
Retinal pigment epithelium
Serous retinal detachment
Orth SR, Ritz E. The nephrotic syndrome. N Engl J Med. 1998;338(17):1202–11.
Dalvin LA, Fervenza FC, Sethi S, Pulido JS. Shedding light on Fundus Drusen associated with Membranoproliferative Glomerulonephritis: breaking stereotypes of types I, ii, and iii. Retin Cases Brief Rep. 2016;10(1):72–8.
Hassenstein A, Richard G. Choroidal neovascularisation in type II membranoproliferative glomerulonephritis, photodynamic therapy as a treatment option--a case report. Klin Monatsbl Augenheilkd. 2003;220(7):492–5.
Woo SA, Young Ju H, Hyo Kwon S, Lee JH, Jeong Choi S, Cheol Han D, Duk Hwang S, Hong SY, Jin SY, Gil HW. Reanalysis of membranoproliferative glomerulonephritis patients according to the new classification: a multicenter study. Kidney Res Clin Pract. 2014;33(4):187–91.
Mullins RF, Aptsiauri N, Hageman GS. Structure and composition of drusen associated with glomerulonephritis: implications for the role of complement activation in drusen biogenesis. Eye. 2001;15(Pt 3):390–5.
Leys A, Michielsen B, Leys M, Vanrenterghem Y, Missotten L, Van Damme B. Subretinal neovascular membranes associated with chronic membranoproliferative glomerulonephritis type II. Graefes Arch Clin Exp Ophthalmol. 1990;228(6):499–504.
McCullagh D, Silvestri G, Maxwell AP. Treatment of choroidal neovascularisation secondary to membranoproliferative glomerulonephritis type II with intravitreal ranibizumab. BMJ Case Rep. 2014;2014.
Empeslidis T, Imrani U, Vardarinos A, Menassa N, Banerjee S. Spontaneous resolution of retinal pigment epithelial detachments and visual improvement in patient with MPGN II: a case report. Case Rep Ophthalmol Med. 2012;2012:864198.
Written consent was obtained from the patient for the publication. The authors thank the orthoptists at Japan Red Cross Medical Center, Department of Ophthalmology for collecting and measuring data for the case report and Dr. Seiji Kishi, Department of Nephrology, Graduate School of Biomedical Sciences, Tokushima University, Japan, for assessing the renal biopsy.
Availability of data and materials
All data generated and analyzed during this study are included in this published article.
The authors have no financial conflicts of interest.
Authors and Affiliations
Department of Ophthalmology, Japan Red Cross Medical Center, 4-1-22, Hiroo, Shibuya-ku, Tokyo, Japan
Department of Ophthalmology, Juntendo University Faculty of Medicine, 3-1-3, Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan
Masato Takei, Takenori Inomata & Akira Murakami
Department of Ophthalmology, Seirei Hamamatsu General Hospital, 2-12-12, Sumiyoshi, Naka-ku, Hamamatsu, Shizuoka, Japan
Department of Strategic Operation Management and Improvement, Juntendo University Faculty of Medicine, 3-1-3, Hongo, Bunkyo-ku, Tokyo, Japan
Ebisu Eye Clinic, 1-1-2, Ebisunishi, Shibuya-ku, Tokyo, Japan
Orange Park Medical Center, Jacksonville, FL, USA
Department of Pathology, Japan Red Cross Medical Center, 4-1-22, Hiroo, Shibuya-ku, Tokyo, Japan
MT was a leading author of this manuscript, and participated in information gathering, data analysis and coordination of the case report. AO and TT interpreted patient data regarding fundus changes and edited the manuscript. TI was a major contributor in writing the manuscript and participated in information gathering, literature search and data analysis. TS participated in writing the manuscript and managed the drafting of the final manuscript. YB and TT performed the histological examination of the kidney. AM designed the study and interpreted the patient data. All authors read and approved the final manuscript.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.